To hear about similar clinical trials, please enter your email below
Trial Title:
Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression
NCT ID:
NCT06140082
Condition:
Non-small Cell Lung Cancer
Conditions: Official terms:
Carcinoma, Non-Small-Cell Lung
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Genetic
Intervention name:
GSTP1 A313G （AA）
Description:
Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy
regimen were included in the retrospective and prospective bidirectional cohort study to
collect the basic information of the subjects, including gender, age, smoking history,
primary site, basic liver and kidney function, chemotherapy regimen, etc. The
polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy
termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two
groups.
Arm group label:
Gene wild-type group
Summary:
This study intends to design a retrospective and prospective, cohort study to explore the
association between genetic polymorphism of GSTP1 A313G rs1695 or others and adverse
effects of platinum drugs, aiming to explore the risk factors of myelosuppression caused
by platinum drugs, and provide data support for optimizing anti-tumor chemotherapy
regimen, improve medication safety and improve the compliance of chemotherapy in
patients.
Detailed description:
Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy
regimen were included in the retrospective and prospective bidirectional cohort study to
collect the basic information of the subjects, including gender, age, smoking history,
primary site, basic liver and kidney function, chemotherapy regimen, etc. The
polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy
termination sequencing. To study the risk factors related to myelosuppression during
chemotherapy, and to preliminarily explore the characteristics of myelosuppression caused
by combination chemotherapy with platinum.
Criteria for eligibility:
Study pop:
Patients with non-small cell lung cancer with clear imaging or pathological evidence are
treated with a platinum-containing chemotherapy regimen
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Patients with non-small cell lung cancer with clear imaging or pathological evidence
2. Using a chemotherapy regimen containing platinum
3. Conducted blood routine and biochemical tests
4. Signed informed consent
Exclusion Criteria:
1. Blood routine and other relevant tests were not performed
2. Suffering from primary bone marrow system disease
3. Other reasons for not meeting the experimental requirements
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Start date:
December 1, 2023
Completion date:
December 30, 2025
Lead sponsor:
Agency:
LI YAN
Agency class:
Other
Source:
Qianfoshan Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06140082
